Liposomes in the treatment of malignancy: a clinical perspective
- 31 May 1992
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 12 (3), 231-242
- https://doi.org/10.1016/1040-8428(92)90056-v
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid)Cancer Immunology, Immunotherapy, 1992
- Phase I Trial of ImmTher, a New Liposome-Incorporated Lipophilic Disaccharide TripeptideJournal of Immunotherapy, 1991
- Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivoFEBS Letters, 1991
- Antitumor Activity of Liposome-Encapsulated Doxorubicin in Advanced Breast Cancer: Phase II StudyJNCI Journal of the National Cancer Institute, 1990
- Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomesFEBS Letters, 1990
- Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyEuropean Journal of Cancer and Clinical Oncology, 1989
- Targeting of immunomodulators to mononuclear phagocytes for therapy of cancerAdvanced Drug Delivery Reviews, 1988
- Liposomes as drug carriers in cancer chemotherapyPharmacology & Therapeutics, 1984
- A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesiclesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1981
- Diffusion of univalent ions across the lamellae of swollen phospholipidsJournal of Molecular Biology, 1965